NASDAQ · PYPD
PolyPid Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PYPD: Nov 11, 2026
PolyPid Ltd. Ordinary Shares is expected to report earnings on 11/11/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.46. The reported EPS for the same quarter last year was $-0.37.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.46 | $0.91 | $-0.41 | 3 |
| Dec 2026 | $-0.22 | $0.28 | $-0.56 | 3 |
| Mar 2027 | $-0.27 | $-0.19 | $-0.35 | 2 |
| Jun 2027 | $-0.26 | $-0.19 | $-0.33 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Fintel · The Motley Fool- MarketBeat · Oct 29, 7:02 AM EDTPolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection ProgramPolyPid (NASDAQ:PYPD) outlined plans to expand its commercial and development strategy through 2030 at an investor day, as the company approaches a November 28, 2026, FDA action date for its D-PLEX100 surgical-site infection prevention product candidate. Chief Executive Officer
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- Fintel · Oct 28, 1:59 PM EDTPolyPid Ltd. Introduces PD01B and Outlines D-PLEX₁₀₀ MilestonesPolyPid Ltd. unveiled its expanded pipeline strategy, introducing PD01B, a new product candidate targeting hyper-localized, controlled-release antibiotic treatment of diabetic foot infections. Based on the Company's proprietary Kynatrix technology, PD01B combines doxycycline with
- MarketBeat · Oct 4, 6:02 PM EDTPolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III DataPolyPid (NASDAQ:PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 In
- The Motley Fool · Aug 19, 11:27 AM EDTPolyPid (PYPD) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 12, 2:45 PM EDTPolyPid Advances D-PLEX100; FDA Grants Priority Review(RTTNews) – PolyPid Ltd. (PYPD), an innovative biopharmaceutical company developing long-acting, controlled-release therapies, reported second-quarter 2026 financial results and corporate updates, highlighting FDA acceptance of D-PLEX100's NDA with Priority Review and a commercia
- MarketBeat · Aug 12, 12:04 PM EDTPolyPid Q2 Earnings Call HighlightsPolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA’s acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada. D-PLEX100 is being developed to prevent surgical
- RTTNews · Jul 29, 10:55 AM EDTPolyPid's NDA For D-PLEX100 Receives FDA Priority Review, Stock Up(RTTNews) – PolyPid Ltd. (PYPD) said on Wednesday that the U.S. Food and Drug Administration has accepted its New Drug Application for D-PLEX100 and granted the treatment Priority Review for the prevention of surgical site infections in patients undergoing abdominal colorectal su
- The Motley Fool · May 13, 3:01 PM EDTPolyPid (PYPD) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 13, 2:09 PM EDTPolyPid Q1 Earnings Call HighlightsPolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery. Chief
- RTTNews · Apr 14, 5:11 AM EDTPolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026(RTTNews) – PolyPid Ltd. (PYPD) will present new pharmacokinetic data from its Phase 3 SHIELD II trial evaluating D-PLEX100, an extended-release incisional doxycycline formulation designed to prevent surgical site infections (SSIs), at the ESCMID Global 2026 congress in Munich.
- The Motley Fool · Feb 11, 1:49 PM ESTPolyPid (PYPD) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for PolyPid Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.